UCB Launches Strategic Research Alliance with Weill-Cornell Medical College
News Apr 04, 2014
UCB has announced that it has launched a major strategic research alliance with Weill-Cornell Medical College that aims to convert scientific discovery into transformative health improvements in areas of high patient need.
This research alliance reflects UCB’s belief that science progresses more rapidly when innovation is fostered by strong partnerships with leading academic partners.
UCB will provide funding for three translational research programs over three years in the areas of bone disorders, metabolic disease and rare genetic variant analysis led respectively by Dr. Laurie H. Glimcher, the Stephen and Suzanne Weiss Dean of Weill-Cornell Medical College, Dr. Timothy McGraw, Professor of Biochemistry, and Dr. Ronald Crystal, Chairman of Genetic Medicine.
The research programs are aligned with a key strategy of UCB NewMedicines™ to focus on the discovery of medicines targeting pathways with a high level of genetic and human validation.
Ismail Kola, Executive Vice President, UCB & President, New Medicines, UCB said, “No single organization can work alone to translate cutting-edge fundamental scientific research into transformative medicines for people with severe disease. That is why are creating a super network with trusted scientific partners globally, combining knowledge of patient medical need with understanding of disease mechanisms. This strategic research alliance brings together Weill Cornell’s world class academic research with our discovery team with the shared objective of developing medicines that could transform the lives of people with severe diseases.”
“We are thrilled to enter into this strategic alliance with UCB to drive research discoveries made at the bench into the most advanced treatments for patients in the clinic,” Dr. Glimcher said. “UCB has an accomplished track record of developing first-rate treatments and therapies. With complementary expertise and a common mission - to help patients, improve health and save lives - our alliance will demonstrate the power of academic-industry collaboration.”
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE